Lates News

Contineum Therapeutics (CTNM.US): In Q3 of 2025, the revenue achieved was $0, with the previous value also being $0. The expected value was $5 million. The earnings per share were -$0.45, with the previous value being -$0.40 and the expected value being -$0.51.